Trial Profile
Neoadjuvant Immunoradiation for Stage III Resectable Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 08 Nov 2022 Planned End Date changed from 1 Sep 2022 to 28 May 2024.
- 12 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.
- 12 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2022.